Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts

Oncotarget. 2017 Mar 21;8(12):19074-19088. doi: 10.18632/oncotarget.13572.


Although histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs, thus far, they have been unsuccessful in early phase clinical trials for pancreatic ductal adenocarcinoma (PDAC). One potential reason for their poor efficacy is the tumor stroma, where cancer-associated fibroblasts (CAFs) are a prominent cell type and a source of resistance to cancer therapies. Here, we demonstrate that stromal fibroblasts contribute to the poor efficacy of HDACi's in PDAC. HDACi-treated fibroblasts show increased biological aggressiveness and are characterized by increased secretion of pro-inflammatory tumor-supportive cytokines and chemokines. We find that HDAC2 binds to the enhancer and promoter regions of pro-inflammatory genes specifically in CAFs and in silico analysis identified AP-1 to be the most frequently associated transcription factor bound in these regions. Pharmacologic inhibition of pathways upstream of AP-1 suppresses the HDACi-induced inflammatory gene expression and tumor-supportive responses in fibroblasts. Our findings demonstrate that the combination of HDACi's with chemical inhibitors of the AP-1 signaling pathway attenuate the inflammatory phenotype of fibroblasts and may improve the efficacy of HDACi in PDAC and, potentially, in other solid tumors rich in stroma.

Keywords: AP-1; SAHA; cancer-associated fibroblasts; histone deacetylase inhibitor; pancreatic cancer.

MeSH terms

  • Animals
  • Blotting, Western
  • Cancer-Associated Fibroblasts / drug effects*
  • Cancer-Associated Fibroblasts / pathology*
  • Carcinoma, Pancreatic Ductal / pathology*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Chromatin Immunoprecipitation
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Pancreatic Neoplasms / pathology*
  • Phenotype
  • Real-Time Polymerase Chain Reaction
  • Xenograft Model Antitumor Assays


  • Histone Deacetylase Inhibitors